Blood‐circulating EV‐miRNAs, serum TARC, and quantitative FDG‐PET features in classical Hodgkin lymphoma

Blood‐based biomarkers are gaining interest for response evaluation in classical Hodgkin lymphoma (cHL). However, it is unknown how blood‐based biomarkers relate to quantitative 18F‐FDG‐PET features. We correlated extracellular vesicle‐associated miRNAs (EV‐miRNA), serum TARC, and complete blood count (CBC) with PET features (e.g., metabolic tumor volume [MTV], dissemination and intensity features) in 30 cHL patients at baseline. EV‐miR127‐3p, EV‐miR24‐3p, sTARC, and several CBC parameters showed weak to strong correlations with MTV and dissemination features, but not with intensity features. Two other EV‐miRNAs only showed weak correlations with PET features. Therefore, blood‐based biomarkers may be complementary to PET features, which warrants further exploration of combining these biomarkers in prognostic models.

[1]  R. Boellaard,et al.  The Impact of Semiautomatic Segmentation Methods on Metabolic Tumor Volume, Intensity, and Dissemination Radiomics in 18F-FDG PET Scans of Patients with Classical Hodgkin Lymphoma , 2022, The Journal of Nuclear Medicine.

[2]  D. de Jong,et al.  Extracellular vesicle miRNA predict FDG‐PET status in patients with classical Hodgkin Lymphoma , 2021, Journal of extracellular vesicles.

[3]  D. Kurtz,et al.  Liquid biopsy in lymphoma: Molecular methods and clinical applications. , 2020, Cancer treatment reviews.

[4]  D. Pegtel,et al.  Circulating miRNAs as Biomarkers in Aggressive B Cell Lymphomas. , 2020, Trends in cancer.

[5]  M. Kersten,et al.  Primary therapy and relative survival in classical Hodgkin lymphoma: a nationwide population-based study in the Netherlands, 1989–2017 , 2020, Leukemia.

[6]  H. Kluin-Nelemans,et al.  Interim thymus and activation regulated chemokine versus interim 18F‐fluorodeoxyglucose positron‐emission tomography in classical Hodgkin lymphoma response evaluation , 2020, British journal of haematology.

[7]  Ronald Boellaard,et al.  RaCaT: An open source and easy to use radiomics calculator tool , 2019, PloS one.

[8]  Eva Krčálová,et al.  Metabolic Tumor Volume and Soluble Cytokines Levels in Newly Diagnosed Hodgkin Lymphoma: What It Brings into the Staging Precision? , 2018, Blood.

[9]  George A. Calin,et al.  Clinical utility of circulating non-coding RNAs — an update , 2018, Nature Reviews Clinical Oncology.

[10]  Ronald Boellaard,et al.  Quantitative oncology molecular analysis suite: ACCURATE , 2018 .

[11]  Martin Hutchings,et al.  Prognostic value of baseline metabolic tumor volume in early-stage Hodgkin lymphoma in the standard arm of the H10 trial. , 2018, Blood.

[12]  A. Zelenetz,et al.  Prognostic significance of baseline metabolic tumor volume in relapsed and refractory Hodgkin lymphoma. , 2017, Blood.

[13]  K. Kok,et al.  miR-24-3p Is Overexpressed in Hodgkin Lymphoma and Protects Hodgkin and Reed-Sternberg Cells from Apoptosis. , 2017, The American journal of pathology.

[14]  D. de Jong,et al.  Plasma vesicle miRNAs for therapy response monitoring in Hodgkin lymphoma patients , 2016, JCI insight.

[15]  A. Diepstra,et al.  Biomarkers for evaluation of treatment response in classical Hodgkin lymphoma: comparison of sGalectin‐1, sCD163 and sCD30 with TARC , 2016, British journal of haematology.

[16]  A. Younes,et al.  The immune microenvironment in Hodgkin lymphoma: T cells, B cells, and immune checkpoints , 2016, Haematologica.

[17]  Eric J. W. Visser,et al.  FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0 , 2014, European Journal of Nuclear Medicine and Molecular Imaging.

[18]  Bruce D Cheson,et al.  Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  J. Pruim,et al.  Plasma thymus and activation-regulated chemokine as an early response marker in classical Hodgkin’s lymphoma , 2012, Haematologica.

[20]  R. Gascoyne,et al.  Molecular pathogenesis of Hodgkin's lymphoma: increasing evidence of the importance of the microenvironment. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  G. T. te Meerman,et al.  Serum chemokine levels in Hodgkin lymphoma patients: highly increased levels of CCL17 and CCL22 , 2008, British journal of haematology.

[22]  Ralf Küppers,et al.  The biology of Hodgkin's lymphoma , 2009, Nature Reviews Cancer.